Mhd-Iyad Saadi, MD
Pulmonary Disease · Chandler, AZNPI 1861621336
Payments from drug & device makers
Across 65 payments — averaging $144.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- GSK$259
- Sanofi-aventis U.S. LLC$166
- Johnson & Johnson$114
- Merck$99
- Insmed, Inc.$92
- plus $575 from 17 others
What the payments were for
- Travel & lodging$4955%
- Food & beverage$1,20113%
- Education$7,66682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $8,057 |
| GSK | 14 | $259 |
| Sanofi-aventis U.S. LLC | 2 | $166 |
| Johnson & Johnson(2 entities) | 2 | $114 |
| Merck | 4 | $99 |
| Insmed, Inc. | 4 | $92 |
| United Therapeutics Corporation | 3 | $79 |
| Sanofi | 4 | $67 |
| Viatris Specialty LLC | 2 | $64 |
| Genentech USA, Inc. | 2 | $54 |
| Grifols USA, LLC | 2 | $46 |
| Philips North America LLC | 2 | $37 |
| Boehringer Ingelheim | 2 | $31 |
| Amgen | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Verona Pharma, Inc. | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| AstraZeneca | 2 | $24 |
| Electromed, Inc. | 2 | $21 |
| Mylan Specialty L.p. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Inogen, Inc. | 1 | $9 |
| Itamar Medical Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,983
How this compares
$9,362 in reported general payments places this provider in the 70th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $348,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 392 | $297,555 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 207 | $175,280 |
| Dupixent PenDupilumab | 23 | $128,349 |
| Spiriva RespimatTiotropium Bromide | 46 | $30,037 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,275 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $11,492 |
| EliquisApixaban | 14 | $11,225 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $10,337 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $9,173 |
| Fluconazole | 70 | $8,410 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,330 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 165 | $3,670 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $3,640 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $31 | $389,88491 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $259 | $320,003442 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $24 | $185,616249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Chandler
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
- George ParidesMesa$913K
- Richard SueGilbert$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.